染色体不稳定性（CIN）是神经胶质瘤的关键因素，导致其复杂性、进展和治疗挑战。 CIN 的特点是有丝分裂期间频繁的基因组改变，导致遗传异常并影响细胞功能。这种不稳定性是由多种因素造成的，包括复制错误和有毒化合物。虽然 CIN 在卵巢癌等癌症中的作用已得到充分证明，但它对神经胶质瘤的影响也越来越得到认可。 CIN 通过影响关键的肿瘤途径来影响神经胶质瘤的进展，例如肿瘤抑制基因（例如 TP53）、癌基因（例如 EGFR）和 DNA 修复机制。它驱动肿瘤进化，促进炎症信号传导，并影响免疫相互作用，可能导致不良的临床结果和治疗耐药性。这篇综述通过叙述性方法研究了 CIN 对神经胶质瘤的影响，分析了 PubMed/Medline、EMBASE、Cochrane 图书馆和 Scopus 的数据。它强调了 CIN 在神经胶质瘤亚型中的作用，从成人胶质母细胞瘤和星形细胞瘤到儿童少突胶质细胞瘤和星形细胞瘤。主要发现包括 CIN 对肿瘤异质性的影响及其作为早期检测和监测生物标志物的潜力。针对 CIN 的新兴疗法，例如调节肿瘤突变负荷和 DNA 损伤反应途径的疗法，显示出希望，但也面临挑战。该综述强调需要综合治疗策略和改进的生物信息学工具（如 CINdex）来促进对神经胶质瘤的理解和治疗。未来的研究应侧重于将 CIN 靶向治疗与免疫调节和个性化医疗相结合，以提高患者的治疗效果。© 2024。作者。

Chromosomal instability (CIN) is a pivotal factor in gliomas, contributing to their complexity, progression, and therapeutic challenges. CIN, characterized by frequent genomic alterations during mitosis, leads to genetic abnormalities and impacts cellular functions. This instability results from various factors, including replication errors and toxic compounds. While CIN's role is well documented in cancers like ovarian cancer, its implications for gliomas are increasingly recognized. CIN influences glioma progression by affecting key oncological pathways, such as tumor suppressor genes (e.g., TP53), oncogenes (e.g., EGFR), and DNA repair mechanisms. It drives tumor evolution, promotes inflammatory signaling, and affects immune interactions, potentially leading to poor clinical outcomes and treatment resistance. This review examines CIN's impact on gliomas through a narrative approach, analyzing data from PubMed/Medline, EMBASE, the Cochrane Library, and Scopus. It highlights CIN's role across glioma subtypes, from adult glioblastomas and astrocytomas to pediatric oligodendrogliomas and astrocytomas. Key findings include CIN's effect on tumor heterogeneity and its potential as a biomarker for early detection and monitoring. Emerging therapies targeting CIN, such as those modulating tumor mutation burden and DNA damage response pathways, show promise but face challenges. The review underscores the need for integrated therapeutic strategies and improved bioinformatics tools like CINdex to advance understanding and treatment of gliomas. Future research should focus on combining CIN-targeted therapies with immune modulation and personalized medicine to enhance patient outcomes.© 2024. The Author(s).